Each of these three companies are entering a new era of growth.
In a groundbreaking trial in San Francisco, the U.S. Securities and Exchange Commission (SEC) is testing the boundaries of insider trading laws. The case against former biotech executive Matthew Panuwat...
If you have a Benjamin burning a hole in your pocket, these stocks are a great way to invest it.
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.
There's no guarantee these stocks can generate 100% returns by 2030. But they have a clear path to make it happen.
What's good for Wood and Ark Invest might not be good for other investors.
The price could be right for these three biopharma stocks.
These stocks share several things in common.
After a lousy year of declining prices, these stocks offer yields of 4.7% and 6.1% at recent prices.
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.